Problematic Analysis and Inadequate Toxicity Data in Phase III Apatinib Trial in Gastric Cancer
- PMID: 27528723
- PMCID: PMC5477931
- DOI: 10.1200/JCO.2016.67.3889
Problematic Analysis and Inadequate Toxicity Data in Phase III Apatinib Trial in Gastric Cancer
Comment in
-
Reply to S. Zhang, L. Fornaro et al, and H.J. Lee et al.J Clin Oncol. 2016 Nov 1;34(31):3823-3824. doi: 10.1200/JCO.2016.69.1071. J Clin Oncol. 2016. PMID: 27528726 Free PMC article. No abstract available.
Comment on
-
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.J Clin Oncol. 2016 May 1;34(13):1448-54. doi: 10.1200/JCO.2015.63.5995. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884585 Clinical Trial.
References
-
- Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448–1454. - PubMed
-
- Hu X, Zhang J, Xu B, et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014;135:1961–1969. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical